Skip to main navigation Skip to search Skip to main content

Long-Term Outcomes of Increased Versus Conventional Adalimumab Dose Interval for Patients With Crohn's Disease in Stable Remission: 3-Year Follow-Up of the Randomized Controlled LADI Trial

  • Lisa M.A. van Lierop*
  • , Monique J.C. Devillers
  • , C. Janneke van der Woude
  • , Frank Hoentjen
  • , Annemarie C. de Vries
  • , Reinier C.A. van Linschoten
  • , Fenna M. Jansen
  • , Nathan den Broeder
  • , Dirk J. de Jong
  • , Alexander Bodelier
  • , Rachel L. West
  • , Ingrid A.M. Gisbertz
  • , Tessa E.H. Römkens
  • , Paul J. Boekema
  • , Hanny van Vroenhoven
  • , Maurice W.M.D. Lutgens
  • , Dominique Bierens-Peters
  • , Zlatan Mujagic
  • , Frank H.J. Wolfhagen
  • , Nanne K. de Boer
  • Elsa van Liere, Bas Oldenburg, Myrthe R. Naber, Adriaan A. van Bodegraven, Rosalie C. Mallant-Hent, Andrea E. van der Meulen-de Jong, Pieter C.J. ter Borg, Henri Braat, Jeroen M. Jansen, Rosanna de la Croix-Vingerling, Adrianus C.I.T.L. Tan, Sita V. Jansen, Sanne van der Wiel
*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

1 Downloads (Pure)
Original languageEnglish
Pages (from-to)404-407
Number of pages4
JournalGastroenterology
Volume170
Issue number2
Early online date19 Sept 2025
DOIs
Publication statusPublished - Feb 2026

Cite this